Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing.

By A. Jackson, J. Burchard, D. Leake, A. Reynolds, Janell M. Schelter, Jie Guo, Jason M. Johnson, Lee P. Lim, J. Karpilow, Kim Nichols and 3 more. RNA: A publication of the RNA Society, 2006

817 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/0a5ff74279d8ebaa0bd0e98f9d593b0e19ec48a4

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

Citations in the corpus

RNAi therapeutics: principles, prospects and challenges. (2007, background): “Recent research suggests that siRNAs with a 2' O-Me modification at the second base can significantly reduce off-targeting without compromising the degree of target silencing [70].”
RNAi therapeutics: a potential new class of pharmaceutical drugs (2006, background): “As one alternative, recent published work has reported that off-targeting can be substantially reduced by chemical modification of nucleotides within the seed regio”
Expanding the MicroRNA Targeting Code: Functional Sites with Centered Pairing (2010, background): “In order to systematically analyze these sites, we therefore compiled additional array data from HeLa experiments with similarly transfected miRNAs and siRNAs (Birmingham et al., 2006; Jackson et al., 2006a; Jackson et al., 2006b; Schwarz et al., 2006; Anderson et al., 2008).”
siRNA vs. shRNA: similarities and differences. (2009, background): “shown to be a key determinant in directing off-target effects [167].”
Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis (2017, background): “These modifications and their applications have been the objective of extensive studies (Jackson et al., 2006; Chen et al., 2008), and they have been here designed for customized targets (On-Target-plus by Dharmacon).”
Predicting effective microRNA target sites in mammalian mRNAs (2015, background): “…1—figure supplement 1B , Figure 3 , Figure 3—figure supplement 1B,C , Figure 4 ( Lim et al., 2005 ; Birmingham et al., 2006 ; Schwarz et al., 2006 ; Jackson et al., 2006a ; Jackson et al., 2006b ; Grimson et al., 2007 ; Anderson et al., 2008 ) Figure 1—figure supplement 1C GSM95614, GSM95615,…”
Knocking down barriers: advances in siRNA delivery (2009, background): “2′-O-methyl modifications have also been shown to confer resistance to endo nuclease activity 41 and to abrogate off-target effects when incorporated into the seed region, which corresponds to nucleotides 2-8 on the antisense strand 42 .”
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application (2010, background): “The inhibition of cell growth correlated with silencing of seed-matched off-target transcript”
The promises and pitfalls of RNA-interference-based therapeutics (2009, neutral): “For instance, it has been shown that 2′- O -Me modification”
RNA interference in the clinic: challenges and future directions (2010, background): “Off-target effects of siRNA treatment can account for observed phenotypic changes independently of the target gene of interes”
Current prospects for RNA interference-based therapies (2011, background): “Additionally, incorporation of unlocked nucleic acids (acyclic RNA mimics) 154 makes the RNAs poor ligands for Toll-like receptors.”
On the art of identifying effective and specific siRNAs (2006, background): “While improved algorithms are awaited, position-specific chemical modification of the seed-sequence of the guide siRNA can be used to reduce off-target effect”